Small Cell Lung Cancer Community Engagement Study

This study is looking at new ways to connect with people who have small cell lung cancer (SCLC) for research. It's an observational study, meaning you won't receive any new treatments. Instead, researchers want to see if a remote, direct-to-patient approach can make it easier for people with SCLC to participate in research, specifically a study collecting biospecimens (like blood samples). You'll also be asked about your preferences and needs regarding new treatments and support through surveys. The goal is to understand how to better reach and support the SCLC community in research. We are looking for about 30 participants.

Study design
This is an observational study that is not testing a new treatment. It aims to enroll about 30 participants.
What's involved
You would provide voluntary consent, allow the study team to collect clinical and medical information, and participate in remote blood sample collection. You would also complete an initial and a 3-month follow-up survey.
Compensation
Not stated in the trial record.
Follow-up
You will complete a follow-up survey at 3 months after the initial survey.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06486428

Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies

Active, Not Recruiting
Not specifiedAges 18+Observational
Addario Lung Cancer Medical Institute
~22 participants
Updated 2026-08-04 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 52 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility of conducting trial in SCLC population
Measured over 12 months
Small-cell Lung Cancer
52 sites across 51 states
Tennessee2
Alabama1
Alaska1
Arizona1
Arkansas1
California1
Colorado1
Connecticut1
  • Christine Lovly, MD PhD · PRINCIPAL_INVESTIGATOR · Vanderbilt-Ingram Cancer Center

This trial hasn't published a contact. View it on ClinicalTrials.gov

  • Feasibility of conducting trial in SCLC population12 months

    Percentage of overall eligible subjects enrolled. Percentage of primary SCLC eligible subjects enrolled. Percentage of tSCLC eligible subjects enrolled. Percentage of SCLC eligible subjects enrolled compared to percentage of tSCLC eligible subjects enrolled. Percentage of primary SCLC enrolled subjects completed. Percentage of tSCLC enrolled subjects completed. Percentage of SCLC enrolled subjects completed compared to percentage of tSCLC enrolled subjects completed. Overall reasons for early termination. Reasons for early termination from trial in primary SCLC enrolled. Reasons for early termination from trial in tSCLC enrolled.